Q-omics provides the consensus-scored MIR378F profile across patient tissues and cancer cell-line models. MIR378F expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR378F is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MIR378F RNA expression shows 5,974 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, THCA, and STAD as cancer lineages where MIR378F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR378F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR378F survival associations across molecular data types. MIR378F RNA expression shows survival associations in the most cancer types (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR378F RNA expression–survival associations across cancer types. High MIR378F expression shows unfavorable associations in COAD, STAD, PRAD and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR378F RNA expression.
This table summarizes MIR378F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR378F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR378F shows lower tumor expression in THCA. The THCA box plot shows higher MIR378F RNA expression in normal versus tumor tissue (log2 FC = −0.053, t-test p = .043).
This table shows molecular features associated with MIR378F in patient tissues and cancer cell lines. In patient samples, MIR378F shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
